
    
      The group will consist of 40 healthy volunteers. The study will be mono-centric. The
      repolarisation phase of cardiomyocytes will be evaluated using long - term 12-lead digital
      ECG monitoring. There will be 3 single ECG recordings - randomly after 20 mg of atorvastin,
      80 mg of atorvastatin and placebo, respectively.
    
  